CoChat

Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders

Open access
Hölscher, Christian · 2022 · British Journal of Pharmacology
Cited by 145

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes mellitus and the associated desensitisation of insulin signalling has been identified as a risk factor for progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and others. Glucagon‐like peptide 1 (GLP‐1) is a hormone that has growth factor‐like and neuroprotective properties. Several clinical trials have been conducted, testing GLP‐1 receptor agonists in patients with Alzheimer's disease, Parkinson's disease or diabetes‐induced memory impairments. The trials showed clear improvements in Alzheimer's disease, Parkinson's disease and diabetic patients. Glucose‐dependent insulinotropic polypeptide/gastric inhibitory peptide (GIP) is the ‘sister’ incretin hormone of GLP‐1. GIP analogues have shown neuroprotective effects in animal models of disease and can improve on the effects of GLP‐1. Novel dual GLP‐1/GIP receptor agonists have been developed that can enter the brain at an enhanced rate. The improved neuroprotective effects of these drugs suggest that they are superior to single GLP‐1 receptor agonists and could provide disease‐modifying care for Alzheimer's disease and Parkinson's disease patients. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.15508

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 145

  1. 10.1007/s00210-018-1497-1 · DOI
  2. 10.1038/nrn812 · DOI · Paper page
  3. 10.1016/S1474-4422(02)00133-3 · DOI · Paper page
  4. 10.1177/1533317519899546 · DOI · Paper page
  5. 10.1016/j.amjms.2017.05.002 · DOI
  6. Alexander S. P. H., 2019, THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors, British Journal of Pharmacology, 176, S21
  7. Alexander S. P. H., 2019, THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors, British Journal of Pharmacology, 176, S247
  8. Alexander S. P. H., 2019, THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels, British Journal of Pharmacology, 176, S142
  9. 10.1016/j.jalz.2017.09.011 · DOI · Paper page
  10. 10.1007/s00702-009-0272-3 · DOI
  11. 10.1016/j.pneurobio.2016.10.001 · DOI · Paper page
  12. 10.1001/jamaneurol.2018.4304 · DOI · Paper page
  13. 10.3233/JPD-140364 · DOI · Paper page
  14. 10.1016/j.freeradbiomed.2004.04.007 · DOI
  15. 10.3390/ijms18112493 · DOI · Paper page
  16. 10.1007/s11011-017-0059-4 · DOI
  17. 10.1002/path.5056 · DOI · Paper page
  18. 10.1073/pnas.0901402106 · DOI · Paper page
  19. 10.3233/JAD-180808 · DOI · Paper page
  20. 10.1016/j.neuroscience.2014.02.022 · DOI
  21. 10.4239/wjd.v6.i6.807 · DOI · Paper page
  22. 10.1097/WNR.0000000000000548 · DOI · Paper page
  23. 10.1016/j.ejphar.2018.03.024 · DOI
  24. 10.1007/s11064-017-2250-8 · DOI
  25. 10.3233/JPD-191900 · DOI · Paper page
  26. 10.1054/npep.1999.0757 · DOI
  27. 10.1038/ijo.2015.136 · DOI
  28. 10.1016/j.brainresbull.2019.08.001 · DOI
  29. 10.1124/pr.112.005850 · DOI
  30. 10.1186/1742-2094-11-51 · DOI · Paper page
  31. 10.1111/bph.14471 · DOI
  32. 10.3233/JAD-141791 · DOI · Paper page
  33. 10.1196/annals.1332.005 · DOI · Paper page
  34. 10.1016/j.molmet.2015.07.008 · DOI · Paper page
  35. 10.1111/j.1464-5491.2008.02484.x · DOI · Paper page
  36. 10.1016/j.neurobiolaging.2005.08.021 · DOI · Paper page
  37. 10.1001/archneurol.2011.233 · DOI · Paper page
  38. Dailey G. E., 2007, Using prandial insulin to achieve glycemic control in type 2 diabetes, The Journal of Family Practice, 56, 735
  39. 10.1016/j.neuropharm.2017.08.022 · DOI · Paper page
  40. 10.1042/CS20110374 · DOI · Paper page
  41. 10.2337/db12-0988 · DOI · Paper page
  42. 10.3389/fneur.2018.00292 · DOI · Paper page
  43. 10.1016/j.biopha.2018.10.066 · DOI · Paper page
  44. 10.1016/S0531-5565(00)00149-2 · DOI
  45. 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
  46. 10.1016/j.neuroscience.2012.10.045 · DOI
  47. Edison P. Femminella G. Frangou E. Love S. Busza G. Holmes C. Ritchie C. Lawrence R. McFarlane B. Tadros G. Ridha B. H. &Bannister C.(2020).Evaluating the effects of the novel GLP‐1 analogue liraglutide in Alzheimer's disease (ELAD study). CTAD conference 2020 abstract OC30.
  48. Egefjord L., 2012, Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease ‐ protocol for a controlled, randomized double‐blinded trial, Danish Medical Journal, 59, A4519
  49. 10.1159/000118039 · DOI · Paper page
  50. 10.1080/02699052.2019.1587000 · DOI · Paper page
  51. 10.3233/JAD-121888 · DOI · Paper page
  52. 10.1186/alzrt174 · DOI · Paper page
  53. 10.1186/s13063-019-3259-x · DOI · Paper page
  54. 10.1016/j.neuropharm.2018.02.012 · DOI
  55. 10.4061/2011/436813 · DOI · Paper page
  56. 10.1097/FBP.0b013e32833c8544 · DOI
  57. 10.1177/1479164118788079 · DOI · Paper page
  58. 10.1007/s40263-013-0076-8 · DOI · Paper page
  59. 10.1111/j.1749-6632.1999.tb07839.x · DOI · Paper page
  60. 10.1007/s12035-013-8404-z · DOI
  61. 10.1007/s12035-012-8339-9 · DOI · Paper page
  62. 10.1002/cne.24905 · DOI · Paper page
  63. 10.1186/1742-2094-5-3 · DOI · Paper page
  64. 10.1111/jdi.12420 · DOI · Paper page
  65. 10.1002/jnr.22565 · DOI · Paper page
  66. 10.1097/WNR.0000000000000490 · DOI · Paper page
  67. 10.1016/j.brainres.2015.12.052 · DOI
  68. 10.1371/journal.pone.0158205 · DOI · Paper page
  69. 10.3233/JAD-143090 · DOI · Paper page
  70. 10.1186/1742-2094-5-19 · DOI · Paper page
  71. 10.1042/BST0390891 · DOI · Paper page
  72. 10.1042/BST20140016 · DOI · Paper page
  73. 10.1016/j.neuropharm.2018.01.040 · DOI · Paper page
  74. 10.3389/fnagi.2019.00088 · DOI · Paper page
  75. Hölscher C., 2020, International review of neurobiology: Metabolic drivers and bioenergetic components of neurodegenerative disease, 65
  76. 10.1016/j.neuropharm.2018.11.002 · DOI · Paper page
  77. 10.1007/978-3-7091-7508-8_18 · DOI · Paper page
  78. 10.1016/j.ejphar.2004.02.049 · DOI · Paper page
  79. 10.1007/BF00314304 · DOI · Paper page
  80. 10.1016/j.neuropharm.2017.02.013 · DOI
  81. 10.1111/jnc.13736 · DOI · Paper page
  82. 10.1515/revneuro-2015-0021 · DOI · Paper page
  83. 10.1016/j.brainres.2015.09.035 · DOI
  84. 10.1002/ddr.21297 · DOI
  85. 10.1016/0196-9781(94)90016-7 · DOI
  86. 10.1016/j.neuropharm.2018.02.027 · DOI
  87. 10.1016/j.neuropharm.2017.11.015 · DOI · Paper page
  88. 10.1007/s11064-016-1890-4 · DOI
  89. 10.1007/s11010-016-2678-1 · DOI
  90. 10.1002/jnr.22596 · DOI · Paper page
  91. 10.3233/JAD-2006-9102 · DOI · Paper page
  92. Li C., 2020, The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD, Brain and Behavior: A Cognitive Neuroscience Perspective, 10, e01505, 10.1002/brb3.1505 · DOI · Paper page
  93. 10.1186/s12868-016-0272-9 · DOI · Paper page
  94. 10.3233/JAD-2010-1314 · DOI · Paper page
  95. 10.1016/j.neuropharm.2015.10.002 · DOI
  96. 10.1016/j.ejphar.2016.11.050 · DOI
  97. 10.1523/JNEUROSCI.5180-14.2015 · DOI · Paper page
  98. 10.3389/fphar.2020.00136 · DOI
  99. 10.1007/s12017-012-8199-5 · DOI
  100. 10.1016/j.cmet.2013.11.002 · DOI · Paper page
  101. 10.1023/A:1007627725251 · DOI
  102. 10.1111/j.1463-1326.2011.01357.x · DOI · Paper page
  103. 10.1177/1533317520953041 · DOI · Paper page
  104. 10.1016/j.neuropharm.2013.08.005 · DOI · Paper page
  105. 10.1016/j.bbr.2015.07.024 · DOI
  106. 10.1002/(SICI)1096‐9861(19990111)403:2<261::AID‐CNE8>3.0.CO;2‐5 · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
  107. 10.1016/0361-9230(92)90068-9 · DOI
  108. 10.1007/BF00313602 · DOI · Paper page
  109. 10.3233/JAD-180578 · DOI · Paper page
  110. 10.1371/journal.pone.0214364 · DOI · Paper page
  111. 10.1002/jnr.21349 · DOI · Paper page
  112. 10.11648/j.ajbio.20150301.13 · DOI
  113. 10.3390/ijms22020860 · DOI · Paper page
  114. 10.3233/JAD-180584 · DOI · Paper page
  115. 10.1038/s41598-017-16488-x · DOI · Paper page
  116. 10.1371/journal.pone.0065420 · DOI
  117. 10.1371/journal.pone.0058784 · DOI · Paper page
  118. 10.1016/j.ejphar.2012.12.012 · DOI · Paper page
  119. 10.1016/j.ejphar.2010.10.059 · DOI
  120. 10.1111/j.1463-1326.2010.01259.x · DOI · Paper page
  121. 10.1016/j.ejphar.2016.04.052 · DOI
  122. 10.1016/0166-2236(95)93890-A · DOI · Paper page
  123. 10.1016/j.neuropharm.2017.11.016 · DOI
  124. 10.1111/dom.12269 · DOI · Paper page
  125. 10.3389/fnagi.2019.00302 · DOI · Paper page
  126. 10.1016/j.bbr.2017.03.032 · DOI
  127. 10.1002/mds.26734 · DOI
  128. 10.2217/nmt.13.73 · DOI · Paper page
  129. Talbot K.(2021).Direct demonstration of brain insulin resistance in Alzheimer's and Parkinson's disease dementia and its alleviation with incretin receptor agonists. AD/PD 2021 conference Boston USA
  130. 10.1038/jcbfm.2011.51 · DOI · Paper page
  131. 10.1210/endo.133.6.8243312 · DOI · Paper page
  132. 10.1080/14728222.2018.1487952 · DOI · Paper page
  133. 10.1016/j.ejphar.2017.03.059 · DOI
  134. 10.1016/j.eplepsyres.2018.03.009 · DOI
  135. 10.1016/j.bbr.2018.08.006 · DOI · Paper page
  136. 10.1523/ENEURO.0053-14.2015 · DOI · Paper page
  137. 10.3390/ijms20051050 · DOI · Paper page
  138. 10.3390/ijms19041153 · DOI
  139. 10.1016/j.ejphar.2017.06.029 · DOI
  140. 10.1016/j.npep.2018.07.003 · DOI · Paper page
  141. 10.3233/JPD-191768 · DOI · Paper page
  142. 10.1016/j.bbr.2015.07.021 · DOI
  143. 10.1016/j.peptides.2019.170184 · DOI · Paper page
  144. 10.1016/j.bbrc.2019.01.103 · DOI · Paper page
  145. 10.1038/srep26859 · DOI · Paper page

Cited by

See all 145

Metadata

Authors
Hölscher, C.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2021-05-29
Volume
179
Issue
4
Pages
695-714
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W3159277791
Cited by
145
References
58
FWCI
11.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.